PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAdo-trastuzumab emtansine
Trastuzumab emtansine
Kadcyla (trastuzumab emtansine) is an antibody drug conjugate pharmaceutical. Trastuzumab emtansine was first approved as Kadcyla on 2013-02-22. It has been approved in Europe to treat breast neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
kadcylaBiologic Licensing Application2024-11-18
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FD: Her2 (human epidermal growth factor receptor 2) inhibitors
— L01FD03: Trastuzumab emtansine
HCPCS
Code
Description
J9354
Injection, ado-trastuzumab emtansine, 1 mg
Clinical
Clinical Trials
165 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50716131539
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C16—21——2
Residual neoplasmD018365————1——1
RecurrenceD012008————1——1
Inflammatory breast neoplasmsD058922————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C80—2——13
Non-small-cell lung carcinomaD002289———3———3
Triple negative breast neoplasmsD064726——11———2
Neoplasm metastasisD009362EFO_0009708——2———2
Pancreatic neoplasmsD010190EFO_0003860C25—1———1
Urinary bladder neoplasmsD001749—C67—1———1
CholangiocarcinomaD018281—C22.1—1———1
Lung neoplasmsD008175HP_0100526C34.90—1———1
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTrastuzumab emtansine
INNtrastuzumab emtansine
Description
Trastuzumab Emtansine (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies; maytansinoid derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1018448-65-1
RxCUI1371041
ChEMBL IDCHEMBL1743082
ChEBI ID—
PubChem CID—
DrugBankDB05773
UNII IDSE2KH7T06F (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Kadcyla – Immunogen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Kadcyla – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 6,626 documents
View more details
Safety
Black-box Warning
Black-box warning for: Kadcyla
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
7,919 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use